Research programme: glaucoma therapeutics - Icagen

Drug Profile

Research programme: glaucoma therapeutics - Icagen

Latest Information Update: 24 Jul 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Icagen
  • Class
  • Mechanism of Action Ion channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Glaucoma

Most Recent Events

  • 24 Jul 2007 Discontinued - Preclinical for Glaucoma in USA (Ophthalmic)
  • 21 Aug 2006 Icagen may selectively consider partnering opportunities for this programme(
  • 21 Aug 2006 Preclinical trials in Glaucoma in USA (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top